相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
-20℃
- 保质期:
12个月
- 英文名:
Recombinant Chemokine C-C-Motif Receptor 5 (CCR5)
- 库存:
1000
- 供应商:
上海信裕
| Organism species | Mus musculus (Mouse) |
| Product No. | xy906Mu01 |
| Source | Prokaryotic expression |
| Host | E.coli |
| Purity | > 95% |
| UOM | 50ug |
| Predicted Molecular Mass | n/a |
| Concentration | n/a |
| Applications | SDS-PAGE; WB; ELISA; IP. |
| Endotoxin Level | <1.0EU per 1µg (determined by the LAL method) |
| Formulation | Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl. |
Stability Test: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37oC for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.
Protein bands: 10kDa, 14kDa, 18kDa, 22kDa, 26kDa, 33kDa, 44kDa and 70kDa.
Double intensity bands: The 26kDa, 18kDa, 10kDa bands are at double intensity to make location and size approximation of proteins of interest quick and easy.
趋化因子C-C-基元受体5(CCR5)重组蛋白Ready-to-use: No need to heat, dilute or add reducing agents before use.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验上海西唐生物科技有限公司 021-55229872, 65333639 www.westang.com 人趋化因子受体5 (CCR5)ELISA 试剂盒 ( 用于血清、血浆、细胞培养上清液和尿液生物体液内 ) 原理 本实验采用双抗体夹心 ABC-ELISA 法。用抗人 CCR5 单抗包被于酶标板上,标准品和样品中的 CCR5与单抗结合,加入生物素化的抗人 CCR5
上海西唐生物科技有限公司 021-55229872, 65333639 www.westang.com 大鼠趋化因子受体 5(CCR5)ELISA 试剂盒 ( 用于血清、血浆、细胞培养上清液和尿液生物体液内 ) 原理 本实验采用双抗体夹心 ABC-ELISA 法。用抗大鼠 CCR5 单抗包被于酶标板上,标准品和样品中的 CCR5 与单抗结合,加入生物素化的抗大鼠 CCR5 ,形成免疫复合物连接在板上
趋化因子介导的生物治疗 趋化因子是一类分子质量为8~11kDa的细胞因子样的分泌蛋白,可分为四类:即C-C,C-X-C,C-X3-C和XC趋化因子。其受体属于七次跨膜结构域G蛋白偶联受体。 将不同类型的趋化因子导人肿瘤细胞,能强化宿主抗肿瘤免疫反应。应用方法包括:将趋化因子基因导人肿瘤细胞,将重组蛋白注射人肿瘤,将趋化因子与肿瘤抗原结合的融合蛋白注入肿瘤,或者将趋化因子基因转导入DC或基质细胞。 使用单一趋化因子的疗法 将CCLl、CCL
技术资料暂无技术资料 索取技术资料




